Comparison · NCT04006457-0c056c62
Vaccine Sub-study: Tdap Vaccination vs Vaccine Sub-study: Meningococcal ACWY Vaccination: Vaccine Sub-study: Number of Participants With AEs
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vaccine Sub-study: Tdap Vaccination vs Vaccine Sub-study: Meningococcal ACWY Vaccination: Vaccine Sub-study: Number of Participants With AEs. Trial comparisons, record NCT04006457-0c056c62. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04006457-0c056c62
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.176 | 0.0619 | 0.41 | wilson | |
| Risk in group 2 | 0.0769 | 0.0137 | 0.333 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0995 | -0.181 | 0.342 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.29 | 0.269 | 19.6 | log | |
| Odds ratio, group 1 over group 2 | 2.57 | 0.235 | 28.1 | log | |
| Number needed to treat, for one more participant with the outcome on Vaccine Sub-study: Tdap Vaccination than on Vaccine Sub-study: Meningococcal ACWY Vaccination | 10 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vaccine Sub-study: Tdap Vaccination | Participants who have received atleast 6 months of treatment with PF-06651600 50mg QD in the study B7981032 were continued to receive the study intervention while participating in this vaccine sub-study. Eligible participants who received the Tdap vaccine with or without the meningococcal ACWY vaccine were enrolled in this sub-study. | 3 | 17 | OG000 |
| Group 2 | Vaccine Sub-study: Meningococcal ACWY Vaccination | Participants who have received atleast 6 months of treatment with PF-06651600 50mg QD in the study B7981032 were continued to receive the study intervention while participating in this vaccine sub-study. Eligible participants who received the meningococcal ACWY vaccine with or without the Tdap vaccine were enrolled in this sub-study. | 1 | 13 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Vaccine Sub-study: Number of Participants With AEs
- Description
- An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Time frame
- From day of vaccination (Day 1) up to 35 days post last dose of vaccine (up to Day 36)
- Population
- SAS was defined as all participants from the vaccine sub study who received at least 1 vaccine (Tdap or meningococcal ACWY).
Source ClinicalTrials.gov
Trial
- Title
- Long-Term PF-06651600 for the Treatment of Alopecia Areata
- NCT number
- NCT04006457
- Phases
- PHASE3
- Conditions
- Alopecia Areata
- Interventions
- PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
- Lead sponsor
- Pfizer
- Results first posted
- 2025-08-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04006457?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04006457-0c056c62